Starting treatment in pediatric HIV infection: try to clarify a gray area

Area of Science:

• Pediatrics
• Infectious Diseases
• Immunology

Background:

• Combination antiretroviral therapy (ART) significantly reduces HIV-related illness and death in children.
• Current guidelines recommend ART for all infants under one year with HIV upon diagnosis.
• Balancing early treatment benefits against long-term resistance and side effects in older asymptomatic children is challenging.

Purpose of the Study:

• To evaluate the optimal timing for initiating ART in HIV-infected children.
• To address the uncertainties in current international guidelines regarding ART initiation for asymptomatic children over one year of age.
• To highlight the need for further research into the benefits of early ART in preserving immune function and preventing HIV encephalopathy.

Main Methods:

• Review and comparison of international treatment guidelines for pediatric HIV.
• Analysis of recent studies on the impact of early ART on B-cell and T-cell function.
• Identification of gaps in current knowledge regarding ART initiation in specific age groups.

Main Results:

• Early ART initiation in infants (<1 year) preserves B-cell and T-cell function.
• Earlier treatment may be crucial for maintaining immune function and preventing HIV encephalopathy.
• International guidelines present a "gray area" concerning ART initiation for asymptomatic children between 2 and 5 years.

Conclusions:

• ART is crucial for managing HIV in children, with early initiation showing benefits in immune preservation.
• The precise timing for starting ART in asymptomatic children over 12 months requires further investigation, particularly for those aged 2-5 years.
• Randomized controlled studies are needed to establish definitive recommendations for ART initiation in this age group.